BioSpace News Archive

BioArctic AB announced that the company and its partner Eisai will present new data on lecanemab at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, to be held in Lisbon, Portugal and virtually, March 5-9.

Royal Philips, a global leader in health technology, announced the launch of Philips CT 5300 system equipped with advanced AI capabilities designed to be used for diagnosis, interventional procedures and screening.

AlzeCure Pharma AB announced that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company’s clinical drug candidate ACD856, which is being developed against Alzheimer’s and other disorders with cognitive impairment.

SN Bioscience Co. Ltd. announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.

Genethon, a non-profit research organization focused on developing gene therapies for rare diseases, marks International Rare Disease Day by highlighting its efforts to bring gene therapies to patients suffering from rare diseases such as limb girdle muscular dystrophies, Crigler Najjar syndrome and Duchenne muscular dystrophy.

AB Science SA will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, highlighted recent updates on the progress made within key areas of its proprietary End-to-End Platform, at the 7th CAR-TCR Summit Europe taking place in London from February 27-29, 2024.

DENTSPLY SIRONA Inc. announced its financial results for the fourth quarter and full year of 2023.

Spineart SA is delighted to announce completion of enrollment in its U.S. IDE trial studying the BAGUERA®C Cervical Disc Prosthesis in patients with single-level cervical disc disease between C3 to C7 compared to a commercially marketed cervical disc implant.

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support dependency in adult patients with short bowel syndrome with intestinal failure.